HCM vs. BHVN, RARE, INSM, PBH, AXSM, ARWR, IDYA, SMMT, CORT, and PTCT
Should you be buying HUTCHMED stock or one of its competitors? The main competitors of HUTCHMED include Biohaven (BHVN), Ultragenyx Pharmaceutical (RARE), Insmed (INSM), Prestige Consumer Healthcare (PBH), Axsome Therapeutics (AXSM), Arrowhead Pharmaceuticals (ARWR), IDEAYA Biosciences (IDYA), Summit Therapeutics (SMMT), Corcept Therapeutics (CORT), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical preparations" industry.
Biohaven (NYSE:BHVN) and HUTCHMED (NASDAQ:HCM) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.
Biohaven's return on equity of 0.00% beat HUTCHMED's return on equity.
Biohaven has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.
88.8% of Biohaven shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 16.0% of Biohaven shares are held by insiders. Comparatively, 3.6% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Biohaven presently has a consensus price target of $51.63, indicating a potential upside of 32.75%. HUTCHMED has a consensus price target of $29.70, indicating a potential upside of 56.23%. Given Biohaven's higher probable upside, analysts plainly believe HUTCHMED is more favorable than Biohaven.
HUTCHMED has higher revenue and earnings than Biohaven.
Biohaven received 58 more outperform votes than HUTCHMED when rated by MarketBeat users. However, 66.60% of users gave HUTCHMED an outperform vote while only 65.43% of users gave Biohaven an outperform vote.
In the previous week, HUTCHMED had 3 more articles in the media than Biohaven. MarketBeat recorded 4 mentions for HUTCHMED and 1 mentions for Biohaven. HUTCHMED's average media sentiment score of 1.41 beat Biohaven's score of 1.20 indicating that Biohaven is being referred to more favorably in the media.
Summary
Biohaven beats HUTCHMED on 8 of the 15 factors compared between the two stocks.
Get HUTCHMED News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HUTCHMED Competitors List
Related Companies and Tools
